logo
logo
EXAS stock ticker logo

Exact Sciences Corporation

NASDAQ•EXAS
CEO: Mr. Kevin T. Conroy J.D.
板块: Healthcare
行业: Medical - Diagnostics & Research
上市日期: 2001-02-01
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
联系方式
5505 Endeavor Lane, Madison, WI, 53719, United States
608-284-5700
www.exactsciences.com
市值
$19.72B
市盈率 (TTM)
-94.3
20.4
股息率
--
52周最高
$103.67
52周最低
$38.81
52周范围
99%
排名62Top 92.6%
1.9
F-Score
改良版 Piotroski 分析
基于 10 年期基本面
疲弱 • 1.9 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2016-2025

财务仪表盘

Q4 2025 数据

营业收入

$878.38M+0.00%
近4季度走势

每股收益

-$0.45+0.00%
近4季度走势

自由现金流

$120.45M+0.00%
近4季度走势

2025 Annual 财报亮点

核心亮点

Total Revenue Grew 17.7% Total revenue reached $3.25B USD in 2025, driven by 20.2% growth in Screening revenue segment.
Net Loss Significantly Narrowed Net loss reduced to $207.9M USD in 2025, a substantial improvement from $1.03B USD loss last year.
Operating Cash Flow Improved Cash provided by operating activities was $491.4M USD, reflecting a $280.9M USD improvement over 2024.
Abbott Merger Agreement Signed Entered Merger Agreement with Abbott for $105.00 cash per share; expected consummation in Q2 2026.

关注风险

Merger Execution Uncertainty Failure or delay in closing the Abbott Merger could materially affect operations and common stock price.
Dependence on Product Success Success heavily relies on commercialization of Screening and Precision Oncology tests in development pipeline.
Regulatory and Reimbursement Risks Uncertainty exists related to healthcare reform, pricing, coverage, and maintaining adequate reimbursement rates.
Need for Additional Capital Additional capital may be required to fully fund strategic plan; financing availability or terms are uncertain.

前瞻展望

Productivity Plan Implementation Implementing multi-year productivity plan targeting over $150M USD in expected annual savings by 2026.
Pipeline Development Investment Expect continued significant investment in R&D to enhance current products and advance pipeline offerings.
Next-Generation MRD Test Launch Plan to introduce next-generation Oncodetect MRD test leveraging MAESTRO technology in 2026.
International Expansion Exploration Exploring opportunities to make Cologuard and Cancerguard tests available outside the U.S. market soon.

同行对比

营业收入 (TTM)

VTRS stock ticker logoVTRS
$14.30B
-3.0%
BAX stock ticker logoBAX
$11.24B
+5.7%
ICLR stock ticker logoICLR
$8.10B
-2.5%

毛利率 (最新季度)

IONS stock ticker logoIONS
96.1%
-0.7pp
BBIO stock ticker logoBBIO
90.0%
+16.5pp
DOCS stock ticker logoDOCS
89.9%
+0.2pp

关键指标

股票代码
市值
市盈率 (TTM)
净资产收益率 (TTM)
负债率
ROIV$21.27B-25.6-18.3%4.0%
EXAS$19.72B-94.3-8.5%43.0%
ILMN$19.61B23.134.9%38.4%

长期趋势

近4季度
营业收入
净利润
经营现金流
4季度营收复合增长率
7.5%
稳定增长
4季度净利润复合增长率
N/M
盈利状态转变
现金流稳定性
100%
现金流表现优异

深度研究

下次财报:2026年4月29日
|
每股收益:-
|
营业收入:-
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表
过去12个月
无数据